Brentuximab Vedotin: all 145 studies that test it
Page 2 of 2. Open to participants first (23), then studies with results posted, then the rest; newest registration first within each.
- CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1.CompletedNCT03217643Phase 2
- Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell LymphomasWithdrawnNCT03205891Phase 1
- Brentuximab Vedotin in Early Diffuse Cutaneous Systemic SclerosisCompletedNCT03198689Phase 2
- Brentuximab Vedotin and BeEAM High-dose Chemotherapy in LymphomasSuspendedNCT03187210Phase 1/2
- Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin LymphomaCompletedNCT03013933Phase 1
- Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by SurgeryActive, not recruitingNCT03007030Phase 2
- TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary SyndromeCompletedNCT02822586Phase 1
- Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid MalignanciesWithdrawnNCT02780011Phase 1
- A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)Active, not recruitingNCT02734771Phase 2
- Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell LymphomaWithdrawnNCT02729961Phase 1/2
- Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICECompletedNCT02686346Phase 1/2
- HD21 for Advanced StagesActive, not recruitingNCT02661503Phase 3
- A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell LymphomaCompletedNCT02616965Phase 1
- A Study of Brentuximab Vedotin in Patients With Hodgkin Lymphoma Unsuitable for Chemotherapy Due to Age, Frailty or Co-morbidityCompletedNCT02567851Phase 2
- Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage SettingTerminatedNCT02499627Phase 2
- Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30+ PTCL PatientsCompletedNCT02497131Phase 2
- Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCLTerminatedNCT02462538Phase 1/2
- Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)WithdrawnNCT02408042Phase 1/2
- Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVDCompletedNCT02298283Phase 2
- Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma.CompletedNCT02292979Phase 2
- Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma PatientsStatus unknownNCT02280993Phase 1
- Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin LymphomasCompletedNCT02280785Phase 2
- Brentuximab Vedotin Followed by ABVD in Patients With Previously Untreated Hodgkin LymphomaStatus unknownNCT02275598Phase 2
- Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin LymphomaTerminatedNCT02254239Phase 1
- BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in R/R HL Patients Non Responding to IGEVCompletedNCT02244021Phase 2
- Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin LymphomaCompletedNCT02243436Phase 1/2
- Brentuximab Vedotin in the Elderly Hodgkin Lymphoma Patients at First Relapse or With Primary Refractory Disease.CompletedNCT02227433Phase 2
- Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin LymphomaCompletedNCT02191930Phase 2
- Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma PatientsCompletedNCT02164006Phase 1
- Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell LymphomaCompletedNCT02086604Phase 1
- Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD)TerminatedNCT01940796Phase 1
- Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin LymphomaCompletedNCT01902160Phase 1
- Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin LymphomaTerminatedNCT01900496Phase 1
- Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell TumorsCompletedNCT01851200Phase 2
- Brentuximab Vedotin + Re-induction Chemotherapy for AMLCompletedNCT01830777Phase 1
- Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell TransplantationCompletedNCT01700751Phase 1
- Brentuximab Vedotin in CD30 Positive Epstein Barr Virus (EBV) Positive DLBCL of ElderlyWithdrawnNCT01671813Not applicable
- Brentuximab Vedotin After Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesWithdrawnNCT01620229Phase 1/2
- Brentuximab Vedotin in Treating Patients With Steroid-Resistant Acute Graft-Versus-Host DiseaseWithdrawnNCT01616680Phase 2
- Brentuximab Vedotin for Steroid Refractory GvHDCompletedNCT01596218Phase 1
- SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)Active, not recruitingNCT01352520Phase 2
- Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)CompletedNCT01026415Phase 1
- Cardiac Safety Study of Brentuximab Vedotin (SGN-35)CompletedNCT01026233Phase 1
- A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive MalignanciesTerminatedNCT00649584Phase 1
- Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic MalignanciesCompletedNCT00430846Phase 1